Inclusion Criteria:

          -  Locally advanced or metastatic solid tumor malignancies that have relapsed or
             progressed after at least one line of therapy and where the following anti-PD-L1 are
             approved: avelumab, atezolizumab or durvalumab

          -  Capable of giving signed informed consent

          -  Aged ≥ 18 years old

          -  Willingness to comply with study procedures and duration

          -  Measurable disease per iRECIST

          -  Contraceptive use for women and men as defined in the protocol

        Exclusion Criteria:

          -  Pregnant or breast-feeding women

          -  ECOG performance status ≥ 2

          -  Evidence of insufficient organ function

          -  Clinically significant cardiovascular disease

          -  Receipt of therapy within 2 weeks prior to Day 1 or five half-lives, whichever is
             shorter or any investigational therapy within 28 days prior to Day 1

          -  Known active central nervous system (CNS) involvement by malignancy

          -  Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis or
             neurodegenerative disease or receipt of medications for these conditions

          -  Currently receiving or likely to require immunosuppressive therapy

          -  Known active infections with Hepatitis B, Hepatitis C or HIV

          -  Live vaccine within 6 weeks prior to start of lympho-conditioning

          -  Known allergy to albumin (human) or DMSO